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Abstract 1 
 2 
Background: There has been a steady increase in the number of studies aiming to identify DNA 3 
methylation differences associated with complex phenotypes. Many of the challenges of epigenetic 4 
epidemiology regarding study design and interpretation have been discussed in detail, however there 5 
are analytical concerns that are outstanding and require further exploration. In this study we seek to 6 
address three analytical issues. First, we quantify the multiple testing burden and propose a standard 7 
statistical significance threshold for identifying DNA methylation sites that are associated with an 8 
outcome. Second, we establish whether linear regression, the chosen statistical tool for the majority of 9 
studies, is appropriate and whether it is biased by the underlying distribution of DNA methylation 10 
data. Finally, we assess the sample size required for adequately powered DNA methylation 11 
association studies.  12 
 13 
Results: We quantified DNA methylation in the Understanding Society cohort (n = 1,175), a large 14 
population based study, using the Illumina EPIC array to assess the statistical properties of DNA 15 
methylation association analyses. By simulating null DNA methylation studies, we generated the 16 
distribution of p-values expected by chance and calculated the 5% family-wise error for EPIC array 17 
studies to be 9x10
-8
. Next, we tested whether the assumptions of linear regression are violated by 18 
DNA methylation data and found that the majority of sites do not satisfy the assumption of normal 19 
residuals. Nevertheless, we found no evidence that this bias influences analyses by increasing the 20 
likelihood of affected sites to be false positives. Finally, we performed power calculations for EPIC 21 
based DNA methylation studies, demonstrating that existing studies with data on ~1000 samples are 22 
adequately powered to detect small differences at the majority of sites. 23 
 24 
Conclusion: We propose that a significance threshold of P<9x10
-8 
adequately controls the false 25 
positive rate for EPIC array DNA methylation studies. Moreover, our results indicate that linear 26 
regression is a valid statistical methodology for DNA methylation studies, despite the fact that the 27 
data do not always satisfy the assumptions of this test. These findings have implications for 28 
4 
 
epidemiological-based studies of DNA methylation and provide a framework for the interpretation of 1 
findings from current and future studies.  2 
 3 
  4 
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Background 1 
There is increasing interest in the role of epigenetic processes in health and disease, with the primary 2 
focus of most epigenetic epidemiological studies being on DNA methylation (DNAm) [1]. Platforms 3 
such as the Illumina 450K Human Methylation microarray (450K array) and the Illumina EPIC 4 
Human Methylation microarray (EPIC array) have enabled the economical, high-throughput profiling 5 
of methylomic variation across large numbers of samples. In recent years a number of epigenome-6 
wide association studies (EWAS), which aim to identify DNAm differences associated with 7 
environmental exposure and disease, have been reported for a range of complex phenotypes including 8 
cancer [2-4],  autoimmune disorders [5-7], psychiatric illnesses [8, 9], neurodevelopmental disorders 9 
[10, 11]
 
and dementia [12, 13]. 10 
 11 
Primarily due to the dynamic nature of the epigenome throughout development, across different cell 12 
types and in response to environmental exposures, much has previously been written regarding the 13 
specific nuances of performing an EWAS compared to a genome-wide association study (GWAS) of 14 
genetic variation [14-16].  However, this literature is mainly focused on study design and 15 
interpretation rather than specific analytical issues relating to the characteristics of the data.  One 16 
concern that has merited some discussion relates to whether the distribution of DNAm data violates 17 
the assumptions of Gaussian linear regression [17, 18], the most commonly used analysis model as it 18 
allows for the inclusion of covariates relating to both biological and technical confounders. For each 19 
molecule of DNA in a single cell, DNAm is a binary entity, in that at any cytosine it is either present 20 
or absent. However, as almost all DNAm studies profile either bulk tissue - comprising multiple cell 21 
types - or a population of purified cells, the analyses are essentially measuring the proportion of cells 22 
(taking a value between 0 and 1) in a sample that are methylated at a specific genomic position [19]. 23 
While across the sites profiled on Illumina arrays DNAm has a bimodal distribution with peaks of 24 
hypomethylation (i.e. unmethylated sites) and hypermethylation (i.e. methylated sites), there is a 25 
significant subset of sites exhibiting intermediate levels of DNAm (proportion of methylated alleles = 26 
~0.5). As the presence/absence of DNAm primarily distinguishes different cell types and tissues, in 27 
studies of a single tissue, which the majority of epigenetic epidemiology studies are, it is unlikely that 28 
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the distribution at individual DNAm sites (the standard unit of analysis in an EWAS) will be bimodal. 1 
However, it is likely that the distributions will be variable and often non-normal, meaning that the 2 
assumption that the residuals of a linear regression fit are normally distributed may not hold. 3 
Furthermore, as DNAm levels are bounded by the limits of 0 and 1 it means that at the extreme ends 4 
of the distribution the variance is compressed. States of hypo and hypermethylation often define cell 5 
types and would not be expected vary biologically within a cell type, beyond any technical noise in 6 
the assay. This is exacerbated by the fact that the sensitivity of the microarray technology is less 7 
precise at these extremes of the distribution, and hence some measured variation is often present for 8 
these theoretically non-variable sites.  This property of the data is called heteroskedasticity, defined as 9 
a relationship between the mean and variance of a dataset, and violates another assumption of linear 10 
regression. Although these concerns should be considered when it comes to deciding the statistical 11 
methodology, it is not currently known whether these violations are sufficient to bias analyses and 12 
introduce false positive or even false negative findings.  13 
 14 
Consistent with studies of other types of genomic variation, another challenge for EWAS is how to 15 
account for the multiple testing burden in a typical analysis; for example, the Illumina EPIC array 16 
assays DNAm at base pair resolution for > 850 000 sites across the genome. Currently, a range of 17 
approaches are used to establish an appropriate significance threshold and there is no standard 18 
significance threshold as is used in GWAS.  A common approach is a Bonferroni correction for the 19 
number of probes on the array [20-23] although this is often presumed to be too conservative as 20 
DNAm values at neighboring probes are known to be correlated [24], and many sites on the array are 21 
non-variable. An alternative, potentially more powerful, approach sets a permissible false discovery 22 
rate (FDR), and identifies the top associated sites that satisfy this criterion [25]. While FDR can be 23 
calculated by generating the empirical null distribution of test statistics [26], it is most commonly 24 
applied using the approach introduced by Benjamini and Hochberg [27]. This makes the assumption 25 
that under the null hypothesis the p-values across individual sites are uniformly distributed [28], 26 
which is not necessarily true. In EWAS it is not uncommon to see inflated test statistics [29, 30], even 27 
in the scenario of no true associations [31], indicating a skewed p-value distribution and perhaps 28 
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reflecting unaccounted confounders such as differences in cellular composition, or certain 1 
environmental exposures such as smoking. This variation in the distribution of p-values across studies 2 
means that the FDR approach often demonstrates variable behaviour making it challenging to 3 
compare results across studies. A better approach would be to estimate the number of independent 4 
tests performed in a EWAS and make the appropriate adjustment to the significance level. Saffari and 5 
colleagues have previously applied the methodology successfully used for GWAS to DNAm data 6 
profiled on the Illumina 450K array [32] in an attempt to establish a standard multiple testing 7 
threshold, however this is yet to be repeated for the EPIC array.   8 
 9 
In this study, we used a large population based study, Understanding Society (n = 1,175), where DNA 10 
extracted from whole blood was profiled using the EPIC array[33, 34] to investigate potential 11 
statistical biases of DNAm association analyses, with the goal of providing recommendations for 12 
future epigenetic epidemiology studies. First, we used a permutation procedure to establish an 13 
appropriate significance threshold that accounts for the multiple testing burden of the EPIC array. 14 
Second, we investigated whether the assumptions of linear regression are satisfied when measuring 15 
DNAm as beta-values and whether any violations bias the results of DNAm studies. Although 16 
transformations of beta-values (e.g. conversion to M-values[18]) have been proposed in order to better 17 
satisfy the assumptions of linear regression, these approaches have not been unanimously adopted by 18 
the community therefore we seek to determine the validity of studies that analysed beta-values. 19 
Finally, we used the significance threshold derived from our simulations to explore the statistical 20 
power of DNAm studies across various scenarios. These results of our analyses will inform the 21 
optimal approach to designing and analysing DNAm data.  22 
 23 
Results 24 
 25 
Estimating a multiple testing corrected significance threshold for the EPIC array 26 
After a stringent quality control (QC) pipeline (see Methods) and the exclusion of DNAm sites that 27 
may be technically biased by either the presence of genetic variants or cross-hybridisation to multiple 28 
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genomic loci, our final dataset included DNAm estimates for 804,826 sites across the autosomes and 1 
X chromosome derived from 1,175 individuals. Applying the Bonferroni correction formula for 2 
multiple testing, the significance threshold for hypothesis testing would be set to P<6.21x10
-8 3 
(0.05/804,826). In order to establish a significance threshold for EPIC array DNAm studies that 4 
controls for the number of independent tests (as opposed to the total number of sites tested), we used a 5 
permutation approach previously applied to GWAS [35] and 450K array DNAm studies [32]. This 6 
method preserves the correlation structure between sites and simulates null association studies by 7 
randomly assigning case control status.  Repeating this process 100 times generates the distribution of 8 
p-values obtained by chance. From this distribution we calculated the 5% family-wise error rate 9 
(FWER) to be 9.42x10
-8
 (Additional File 1: Figure S1). Using the inverse of the Bonferroni 10 
correction formula this is equivalent to correcting for 530,639 independent tests (0.05/9.42x10
-8
), a 11 
reduction of 34.1% compared to the total number of sites included in the analysis.  12 
 13 
Estimating multiple testing corrected significance threshold for a genome-wide DNAm study 14 
As DNAm microarrays only profile a subset of the ~28 million potentially methylated sites in the 15 
human genome, the threshold calculated above is specific to an EPIC array-based experiment and 16 
hence we will refer to it as an “experiment-wide significance threshold”. Next, we were interested in 17 
using our permutations to extrapolate from this experiment-wide threshold to a significance threshold 18 
that accounts for all variation in DNAm across the genome. Given the correlation in DNAm between 19 
proximal DNAm sites, the content of the EPIC array provides some information about neighboring 20 
sites that are not directly profiled. Continuing to increase the genomic coverage of the microarray 21 
should, therefore, have diminishing returns in terms of novel association tests as we can use the sites 22 
present on the array to infer the status of other unmeasured neighboring sites. In order to model the 23 
information gain in terms of number of independent tests as the coverage of the microarray increases, 24 
we applied our permutation procedure to subsamples of DNAm sites at increasing densities (xi=5%, 25 
15%, ..., 95%). For each density, we estimated the significance threshold 100 times and calculated the 26 
mean 5% FWER (denoted PTi  for density i%). These estimated PTi values are plotted in Figure 1a, 27 
and demonstrate the expected monotonic, non-linear relationship where PTi becomes more significant 28 
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as the number of sites sampled increases. Each PTi value was then used to calculate the effective 1 
number of independent tests (mi) at density i% using the inverse of Bonferroni formula (mi = 2 
0.05/PTi). Again, we observe a monotonic relationship where the effective number of tests increases as 3 
the proportion of sites sampled increases (Figure 1b; Additional File 2 Table S1). As the proportion 4 
of additional independent tests should decrease as the number of sites increases, this relationship is 5 
expected to be non-linear and converge to an asymptote which represents the total number of 6 
independent tests across the genome. These properties can be represented by the Monod function, 7 
which was originally proposed for the growth of microorganisms but is applicable to scenarios where 8 
subsequent growth is increasingly restricted over time. In this application, continually increasing the 9 
number of sites profiled in an experiment leads to smaller and smaller increments in the number of 10 
independent sites tested until all variation in DNAm is captured. This upper limit represents the total 11 
number of independent tests in the genome and is the value we want to estimate in order to determine 12 
the genome-wide multiple testing burden. We observe that this non-linear behaviour only starts to 13 
appear after ~600,000 sites. Fitting a Monod function to the subsampling results, we estimated the 14 
asymptote to be 5,803,067 (Figure 2a) reflecting the total number of independent tests across the 15 
DNA methylome. Compared to the total number of sites in the genome, this is a reduction of 79.3%. 16 
Calculating the Bonferroni corrected significance threshold based on this estimate gives a methylome-17 
wide significance threshold of 8.62x10
-9 
(=0.05/5.80x10
6
) (Figure 2b). Comparing this to a 18 
Bonferroni corrected significance threshold for all sites in the genome of 1.79x10
-9 
(0.05/2.8x10
7
), our 19 
estimate is almost an order of magnitude smaller. The Monod function was also fitted to the 20 
subsample 95% confidence interval (CI) limits, estimating a 95% CI for the asymptote of 1.69x10
6
 to 21 
3.36x10
13
, which equates to a 95% CI of 2.97x10
-8
 to 1.49x10
-15
 for the methylome-wide significance 22 
threshold.  23 
 24 
Testing the assumptions of linear regression for DNAm analyses 25 
To assess whether the assumptions of linear regression are satisfied, we performed an EWAS of age, a 26 
trait known to robustly co-vary with DNAm at multiple loci [21, 36]. The four assumptions of linear 27 
regression were assessed using four statistical tests implemented within the gvlma R package [37]. 28 
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Specifically, these were tests for i) skewness, an asymmetrical distribution of the residuals, ii) 1 
kurtosis, a non-bell-shaped distribution of the residuals, iii) incorrect link function, a non-linear 2 
relationship between independent and dependent variables, and iv) heteroskedasticity, inconstant 3 
variance of the residuals (Additional File 1: Figure S2). In addition, a global test was performed 4 
providing an omnibus test of the four individual statistical tests. QQ plots of all five tests 5 
demonstrated dramatic inflation of p-values smaller than expected by chance (Additional File 1: 6 
Figure S3), indicating that the null hypothesis that DNAm data meets the assumptions of linear 7 
regression can be rejected for a large number of DNAm sites. Based on the experiment-wide 8 
significance threshold we previously derived for the EPIC array (i.e. P < 9.42x10
-8
), 71.8% of sites 9 
rejected the null hypothesis for at least one assumption, with the majority of sites having non-normal 10 
residuals that exhibited evidence of excess skewness (41.3%) or excess kurtosis (67.6%) (Table 1). 11 
Furthermore, the specific DNAm sites whose residuals were skewed overlapped with the sites whose 12 
residuals were kurtotic (i.e. either highly or shallowly peaked) (Figure 3). A much smaller percentage 13 
of sites reject the null hypothesis in favour of a non-linear model (7.4%) or heteroskedasticity (4.3%).  14 
 15 
 
Global Skewness Kurtosis Link Function Heteroskedasticity 
N reject null hypothesis 577,919 332,457 544,460 59,572 35,001 
% reject null hypothesis 71.8 41.3 67.6 7.4 4.3 
Table 1: Summary of DNA methylation sites significantly rejecting the assumptions of linear 16 
regression. For each of the 5 tests performed by the gvlma package the number and percentage of 17 
DNA methylation sites with significant p-values (P < 9.42x10
-8
) are reported.  18 
 19 
Characterising DNAm sites that infringe the assumptions of linear regression 20 
In order to propose guidelines for future EWAS studies, we were interested in whether DNAm sites 21 
that performed poorly in the gvlma tests could be characterized by common features such as DNAm 22 
level or variability. First, we considered the level of DNAm at each site, hypothesising that sites 23 
which are located at the extremes of the distribution would be more likely to violate the assumptions 24 
of the tests. We observed that the sites with the most significant p-values in the gvlma tests (i.e. those 25 
11 
 
with the largest –log10 p-values) are generally either hypo- or hypermethylated (Additional File 1: 1 
Figure S4). Furthermore, by grouping sites based on their mean DNAm level we can pinpoint where 2 
in the distribution of DNAm values the assumptions are typically not satisfied. We observe a U-3 
shaped relationship whereby sites with DNAm levels at the extremes (i.e. approaching 0 or 1), are 4 
more likely to violate the assumptions compared to sites with intermediate levels of DNAm (Figure 5 
4; Additional File 2: Table S2). This pattern generally holds for all four tests, but is most apparent 6 
for tests of skewness and kurtosis. Of interest, the relationship is not symmetrical, with the first two 7 
bins on the left of the distribution (containing sites with means of between 0 and 0.2) but only one bin 8 
on the far right of the distribution (containing sites with means of between 0.9 and 1.0) showing 9 
elevated mean –log10 p-value compared to the middle seven bins. Second, we considered site 10 
variability, hypothesising that sites with low levels of variation would be more likely to violate the 11 
test assumptions. Using the standard deviation to index variability, we observed that sites with lower 12 
standard deviations had larger -log10 p-values when testing the assumptions of linear regression 13 
(Additional File 1: Figure S5). This was most evident for the tests of skewness, kurtosis and 14 
heteroskedasticity, in particular for sites with a standard deviation < 0.02 (Figure 5; Additional File 15 
2: Table S3). A more complex pattern was seen for the link function test, where the most variable 16 
probes and the second group of least variable probes had the highest –log10 p-values. Using an 17 
alternative non-parametric method to characterize sites as ‘variable’ (range of middle 80% of values 18 
>5%) or ‘non-variable’, we observed a similar pattern of results (Additional File 1: Figure S6; 19 
Additional File 2: Table S4) where non-variable sites were more likely to reject the assumptions of 20 
linear regression compared to variable sites. Taken together, these findings suggest that sites with 21 
extreme DNAm levels or low variation are most likely not to satisfy the assumptions of linear 22 
regression. These characteristics are not unrelated because sites with low levels of variation are 23 
typically located at the boundaries of the distribution of DNAm (Additional File 1: Figure S7).  24 
 25 
Recently, M-values have been proposed as an alternative to beta-values in EWAS analyses of traits 26 
and exposures due to their more desirable statistical properties [18]. Although a direct comparison of 27 
beta-values and M-values is beyond the scope of this manuscript, we repeated our analyses on M-28 
12 
 
values to further interpret the results presented above. Using our experiment-wide significance 1 
threshold, 70.1% of DNAm sites demonstrated significant bias of at least one assumption when using 2 
M-values; that is just 1.09% less than the original analysis based on beta-values (Additional File 2: 3 
Table S5). Furthermore, 85.9% of DNAm sites that are considered statistically inappropriate based on 4 
beta-values were also classed as statistically inappropriate when analysed as M-values. As with the 5 
beta-value analysis, the primary assumption violated by M-values related to the shape of the 6 
distribution of residuals. In fact, a comparable number of sites demonstrated excess kurtosis 7 
regardless of whether beta-values (67.6%) or M-values (66.7%) were used. Furthermore, albeit more 8 
subtly, DNAm sites with methylation levels at the extreme ends of the distribution were more likely to 9 
fail the statistical tests (Additional File 1: Figure S8), consistent with the results of the analysis using 10 
beta-values.   11 
 12 
Evaluating the impact on DNAm studies of sites that do not meet the assumptions of linear regression  13 
The primary concern about using an invalid analytical model is the risk of either reporting false 14 
positive or false negative findings in tests of association. As linear regression is considered robust to 15 
violations of the assumptions, we next explored whether sites that violated an assumption were more 16 
likely to be significant in a DNAm analysis using a linear regression model. Using our simulated null 17 
association studies, DNAm sites were ranked by their association p-value to calculate the mean rank 18 
across the simulations. In a scenario where all sites are equally likely to be associated and there is no 19 
bias in the analysis, the distribution of these mean ranks should be symmetrical and unimodal with a 20 
mean of 402,413.5. Any skew in the distribution, or the presence of outliers and/or multiple peaks, 21 
would indicate an underlying bias in which DNAm sites are often identified as significant or not. We 22 
found that the distribution of the mean rank was normally distributed with a mean of 402,446 23 
(Additional File 1: Figure S9), similar to the expected value. We observed no association between p-24 
values from the gvlma tests and a DNAm site’s mean rank indicating that even highly significant 25 
rejections of the assumptions of linear regression do not bias EWAS results in terms of either false 26 
positives or false negatives (Figure 6; Additional File 1: Figure S10; Additional File 2: Table S6).   27 
 28 
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Estimating the power of an EPIC array DNAm study 1 
The power of a test is defined as the probability that it correctly rejects the null hypothesis when the 2 
alternative hypothesis is true. As with other types of genomic analyses, large sample sizes are required 3 
for EWAS in order to obtain the statistical power required to identify a significant non-zero effect 4 
with a p-value that survives the adjustment for multiple testing. Having derived an appropriate 5 
multiple testing corrected significance threshold for the EPIC array, we investigated the typical 6 
sample sizes required for a DNAm study using this platform. In order to estimate power we need to 7 
know the sample size, multiple testing threshold, expected effect size and variance. While the first 8 
three of these parameters will remain constant for a particular study, the variance of DNAm will vary 9 
across sites. This means that a single power calculation, perhaps based on an average probe, provides 10 
limited information about the overall power of a DNAm study. We therefore performed a power 11 
calculation for each individual site on the EPIC array and then established the proportion of sites that 12 
surpass a specific power threshold. The estimated power for a single association test across a range of 13 
standard deviations and sample sizes for a binary phenotype (as would be tested in a disease case-14 
control study) are shown in Table 2. For example, to detect a mean difference of 2% with 500 cases 15 
and 500 controls (total N = 1000), we have 100% power at sites with a standard deviation <= 0.03. 16 
Performing separate power calculations tailored by the variance of each site, we plotted power curves 17 
for a range of typical DNAm studies (Figure 7). This analysis demonstrates that when N=200 (100 18 
cases and 100 controls), 85% of sites have >80% power to detect an effect of 5% (yellow line in 19 
Figure 7b), and when N=1000 (500 cases and 500 controls), 81% of probes have >80% power to 20 
detect an effect of 2% (light blue line in Figure 7a). While these examples provide a general 21 
overview of power for EPIC array studies, the results are also available for browsing in an interactive 22 
web application (https://epigenetics.essex.ac.uk/shiny/EPICDNAmPowerCalcs/) where the 23 
parameters can be adjusted in order to generate bespoke power calculations allowing researchers to 24 
assess the power of their individual study.  25 
 26 
 27 
14 
 
Sample Size Standard Deviation  
  0.01 0.03 0.05 0.07 0.09 0.15 
Mean Difference = 2% 
100 100% 1.26% 0.03% 0.00% 0.00% 0.00% 
200 100% 21.4% 0.45% 0.04% 0.01% 0.00% 
500 100% 97.8% 17.6% 1.43% 0.19% 0.01% 
1000  100% 100% 82.7% 19.7% 3.22% 0.06% 
Mean Difference = 5% 
100 100% 99.1% 24.4% 2.18% 0.29% 0.01% 
200 100% 100% 93.0% 32.0% 6.07% 0.11% 
500 100% 100% 100% 99.4% 78.4% 4.81% 
1000 100% 100% 100% 100% 100% 45.8% 
Table 2: Summary of statistical power to significantly detect differential methylation between 1 
cases and controls.  Presented are example power calculations for a range of scenarios, varying effect 2 
size, sample size and variance for a binary phenotype. Power calculations are for a two-sided, two-3 
sample t-test with a significance threshold of P<9.42x10
-8
. The sample size is the total number of 4 
samples with a 50:50 split between groups. 5 
 6 
Discussion 7 
This study used a large DNAm dataset generated using the Illumina EPIC array to assess the 8 
statistical properties that influence the analytical design for hypothesis testing in epigenome-wide 9 
association studies. We estimated that there are 530,639 independent tests in a whole blood EPIC 10 
array DNAm study, which equates to a corrected significance threshold of 9.42x10
-8
. For ease, we 11 
propose 9x10
-8
 would be an appropriate EPIC array experiment-wide significance threshold that 12 
should be adopted by the field to minimize the reporting of false positives. Although this EPIC array 13 
experiment-wide threshold is not substantially different to a Bonferroni correction for the actual 14 
number of tests, our estimate is comparable to that proposed using a similar methodology to data from 15 
15 
 
the older 450K array [32], which includes approximately half the number of sites (P = 2.4x10
-7
) that 1 
were converted to M-values. Our results indicate that the correlation in DNAm across sites included 2 
on the Illumina EPIC array is relatively small and does not encompass large genomic regions; Saffari 3 
and colleagues also observed that strong correlations between neighboring sites were typically only 4 
observed within 1 kilobase [32], consistent with the minimal reduction from number of actual tests to 5 
number of independent tests we report. This challenges the argument that a Bonferroni correction is 6 
too conservative and therefore a more relaxed multiple testing threshold can be applied. Existing and 7 
future studies which report results at a more lenient threshold, particularly those with small sample 8 
sizes and lower statistical power should be interpreted with caution.  9 
 10 
We attempted to extrapolate from the experiment-wide threshold for the EPIC array to estimate an 11 
appropriate threshold for all potential tests across the genome, including those not currently profiled 12 
by the EPIC array, by using simulations to profile how the number of independent tests changes as the 13 
coverage of the microarray increases. At sufficient density, the number of independent tests should 14 
plateau; however this behaviour was not really evident across the range of densities we were able to 15 
simulate, suggesting that the EPIC array does not interrogate a large part of the variation in DNAm 16 
across the genome. Therefore, our estimate of the number of independent tests in the genome is likely 17 
to be imprecise. Moreover, given the wide confidence interval around the estimated genome-wide 18 
multiple testing burden, we recommend this result is taken with some caution. Future large population 19 
based studies that include more DNAm sites across the genome would be required to address this 20 
question. We propose that our experiment-wide significance threshold should be adopted for all future 21 
EPIC array EWAS. The use of a standardized significance threshold would benefit the field by 22 
providing a common standard for reporting associations and facilitate the comparison of results across 23 
different studies. While the threshold has been determined to minimize the reporting of false 24 
positives, it does not prevent them entirely; prudent study design and effective control of confounders 25 
are still required for high quality EWAS studies. Furthermore, replication of associations across 26 
independent datasets is still required to validate robust associations.  27 
 28 
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We also tested the assumptions of linear regression, the most commonly used tool for identifying 1 
associations between differential DNAm and a trait, when measuring DNAm using beta-values (i.e. as 2 
a proportion) and conclude that the majority of sites do not satisfy the assumption of normally 3 
distributed errors. This was particularly the case for DNAm sites that have low levels of variation or 4 
are located at the extreme ends of the distribution. While we use our experiment-wide p-value 5 
threshold to quantify the number of probes not satisfying these assumptions in order to gauge the 6 
pattern of results, we caution against using this threshold to classify sites as passing or failing these 7 
assumptions. As the statistical evidence required to reject the null hypothesis in these tests is unlikely 8 
to equate to the degree of violation of the assumption needed to influence the results of the regression 9 
analysis, it may not follow that sites that fail these tests will lead to incorrect conclusions if a linear 10 
regression model is used. As these assumptions were tested on an EWAS of chronological age, it is 11 
possible that our results are specific to this particular analysis. Furthermore, we used a European adult 12 
whole blood cohort as a basis for our assessment, which may mean that the results are not applicable 13 
to studies of other tissues, cell-types, ages or ethnicities. It is also likely that these violations of these 14 
assumptions will be more important for studies based on smaller sample sizes.  For these reasons, 15 
rather than report a list of DNAm sites that do not satisfy the assumptions, we focused on 16 
characterising these sites in order to provide general guidelines. Although the specific sites that not do 17 
vary within a sample may differ between studies, we predict that it is always the non-variable sites 18 
that fail the tests of the assumptions. Some studies remove non-variable sites prior to hypothesis 19 
testing[38, 39] [40] and our results support such a filtering step. However, as we found no evidence 20 
that the lack of normal residuals, an incorrectly specified link function, or heteroskedasticity leads to 21 
either false positive or false negative associations, our data also suggests that this is not strictly 22 
necessary. A number of studies have used transformations of beta-values, for example using log ratios 23 
of methylation percentage referred to as M-values in order to obtain a normal distribution[3, 18, 41] 24 
or regression based on an alternative distribution (e.g. beta regression[42]); our results show that the 25 
use of linear regression with beta values in DNAm studies, even if the data do not satisfy the standard 26 
assumptions of this test, does not appear to lead to biased results. Despite considering the four key 27 
assumptions of linear regression, we did not specifically investigate the effect of outlier DNAm 28 
17 
 
values, which may arise due to either technical or biological artefacts (e.g. rare SNP effects). The 1 
presence of outliers can introduce false positive associations as linear regression estimates are derived 2 
by minimising the sum of the residuals, therefore extreme values, which would lead to large residuals, 3 
can lead to larger, and therefore significant, estimated slope coefficients.   4 
 5 
Finally, we performed power calculations to ascertain the sample size required for EPIC array studies 6 
using our proposed experiment-wide significance threshold. Most complex phenotypes are expected 7 
to be associated with small effects (typically < 5% difference between cases and controls), and our 8 
calculations indicate that with a sample size of 500 cases and 500 controls, 81% of sites have >80% 9 
power to detect an effect of 2%. This estimate should be reassuring to the epigenetic community, as 10 
there are an increasing number of studies approaching or surpassing this sample size [9, 43-46]. Our 11 
approach advances previous efforts[47] by taking into account the individual properties of each 12 
DNAm site and uses an empirically derived significance threshold to provide an overview of power 13 
across the EPIC array. Finally, we have developed an online tool 14 
(https://epigenetics.essex.ac.uk/shiny/EPICDNAmPowerCalcs/ ) where users can perform their own 15 
bespoke calculations to quantify the power of their specific study for individual DNAm sites; we are 16 
currently extending this power calculation application for use with quantitative trait variables, and 17 
will implement an updated version in the near future. 18 
 19 
Conclusions 20 
We show that linear regression is a valid statistical methodology for DNAm studies, despite the fact 21 
that the data do not always satisfy the assumptions of the test. Additionally, we propose that a 22 
significance threshold of P < 9x10
-8 
should be adopted to adequately control the false positive rate for 23 
EPIC array based analyses and should be accepted as a standard for reporting results. These findings 24 
have implications for epidemiological-based DNAm studies and provide a framework for the 25 
interpretation of findings from current and future studies.  26 
 27 
Methods 28 
18 
 
All analyses were performed using the statistical language R [48]. 1 
 2 
Genomic-wide profiling of DNAm in Understanding Society  3 
The DNAm dataset generated as part of the Understand Society study has been analysed in two 4 
previously published studies [34, 49] and a detailed description of the sample, DNAm data generation 5 
and data preprocessing can be found in the original publication [34]. Briefly, Understanding Society 6 
(https://www.understandingsociety.ac.uk) is a longitudinal panel survey of 40,000 UK households 7 
which has collected sociodemographic information, biomedical measures and blood samples from 8 
participants. DNA was extracted from whole blood samples to facilitate genomic profiling including 9 
DNAm.   10 
 11 
DNAm data preprocessing 12 
DNAm was profiled for a subset of 1,193 individuals from the Understanding Society study using the 13 
Illumina Infinium HumanMethylationEPIC BeadChip. Raw signal intensity data were processed from 14 
idat files through a standard pipeline using the bigmelon [49] and wateRmelon [50] packages in R.  A 15 
number of quality control steps were performed to these data prior to normalization. First, outlier 16 
samples were identified using principal component analysis and mahalanobis distance equivalents, 17 
second, successful bisulphite conversion was confirmed using control probes, third the ages of the 18 
samples were estimated using the Horvath Epigenetic Clock algorithm [51] and compared to reported 19 
age at sampling, and fourth visualisation of principal components. These data were then normalized 20 
using the dasen method [50] ,which performs background adjustment and between-sample quantile 21 
normalization of methylated (M) and unmethylated (U) intensities separately for Type I and Type II 22 
probes. A second round of sample filtering was then performed excluding samples that were either 23 
dramatically altered as a result of normalisation or samples that had > 1% of sites with detection p-24 
value > 0.05. DNAm sites were filtered to exclude those with a bead count < 3 or > 1% of samples 25 
with detection p-value > 0.05. The raw DNAm data of the final sample set was then re-normalized 26 
with the dasen method. Prior to data analysis, SNP probes, probes with non-specific binding, probes 27 
affected by common SNPs [52], and 65 probes annotated to the Y chromosome were additionally 28 
19 
 
removed. The final dataset contained 1,175 individuals and 804,826 DNAm sites (787,400 annotated 1 
to autosomes, and 17,426 annotated to the X chromosome).  2 
 3 
Estimating a significance threshold for DNAm studies using the EPIC array 4 
To estimate an experiment-wide significance threshold for the EPIC array, we applied the permutation 5 
procedure previously described by Dudbridge and Gusnanto [35]. For each permutation, 50% of our 6 
1,175 samples (n = 557) were randomly assigned as “cases” and 50% (n = 558) as “controls” to 7 
simulate a null EWAS (i.e. no differences between cases and controls). Each of the 804,826 sites was 8 
then tested for association with this simulated phenotype using a linear regression model including 9 
sex, age, and six estimated cellular composition variables (B cells, CD8 T cells, CD4 T cells, 10 
monocytes, granulocytes, natural killer T cells) [53, 54] as covariates. We repeated this procedure 11 
1000 times recording the smallest p-value (i.e. the most significant) from each permutation.  The 12 
EPIC array significance threshold was estimated by taking the 5
th 
percentile point of these 1000 13 
minimum p-values representing the 5% family-wise error rate (FWER).  14 
 15 
Estimating a genome-wide significance threshold for DNAm studies  16 
In order to extrapolate from our experiment-wide significance thresholds to one appropriate for 17 
genome wide DNAm association studies, we implemented the subsampling procedure also 18 
implemented by Dudbridge and Gusnanto [35]. Briefly, to simulate experiments with a reduced 19 
number of sites that capture a smaller proportion of genome-wide variation, sites were randomly 20 
subsampled at a range of densities (xi=5%, 15%, ..., 95%; i=1, 2, ..., 10). From each permutation, the 21 
smallest p-value across the subset of sites was extracted and the 5
th 
percentile point across all 1000 22 
minimum p-values was recorded. This subsampling was repeated 100 times and the mean, 2.5 and 23 
97.5 percentile points were calculated to set the significance threshold (PTi) and confidence intervals 24 
for density i. At low densities, where the coverage is sparse, it is assumed that all included DNAm 25 
sites will be independent and a Bonferroni correction for multiple testing is appropriate. As coverage 26 
increases, correlations between neighboring sites mean that the number of additional independent tests 27 
decreases. In other words, continually increasing the number of sites studied has diminishing returns 28 
20 
 
in terms of the increase in additional variation captured. Therefore, as the number of sites profiled in 1 
an experiment increases, the effective number of independent tests converges to an asymptote. To 2 
estimate the value of this asymptote, we fitted a Monod function across the site densities and their 3 
estimated number of independent tests. For each of the site densities (xi), the effective number of 4 
independent tests (mi), was calculated by using the inverse of the Bonferroni correction for multiple 5 
testing (mi = 0.05/PTi). A Monod function, originally a mathematical model for bacterial population 6 
growth with limited resources, takes the form: 7 
 8 
where u is the limit and k is the half-saturation parameter, their values given by: 9 
 10 
 11 
This function was fitted using a least squares approach in R to find the value of u, which represents 12 
the number of independent tests in the entire DNA methylome. To calculate the methylome-wide 13 
significance threshold we applied the Bonferroni correction using this estimate (Pgenome = 0.05/u). 14 
 15 
Testing the assumptions of linear regression models used in DNAm studies 16 
To assess the validity of linear regression models in studies of DNAm, an EWAS of age was 17 
performed including sex, processing chip and six estimated cellular composition variables (B cells, 18 
CD8 T cells, CD4 T cells, monocytes, granulocytes, natural killer T cells) [53, 54] as covariates. For 19 
each of the 804,826 models (one per DNAm site) we tested for violations of the assumptions of linear 20 
regression using the gvlma (Global Validation of Linear Model Assumptions) R package [37]. This 21 
package performs four tests to test the performance of the model fit with regards to the four 22 
assumptions of a linear regression: linearity, homoskedasticity, uncorrelatedness and normality of the 23 
residuals (Additional File 1: Figure S2). The gvlma package provides a numerical measure of 24 
violation through significance testing for skewness, kurtosis, link function, and heteroskedasticity. 25 
Briefly, the package calculates a directional test statistic for each assumption using the standardized 26 
𝑚 = 𝑓(𝑥, 𝑢, 𝑘) =  
𝑢𝑥
𝑘 + 𝑥
 
𝑓(𝑘) =  
𝑢
2
 
𝑓(∞) =  𝑢 
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residuals from the fitted linear model. These test statistics are each compared to a 1 degree-of-1 
freedom chi-square distribution to calculate a p-value for hypothesis testing. In addition to obtaining a 2 
p-value for each of these four tests, the software also generates a “global” p-value, which is an 3 
omnibus test of the four others. The global test statistic is the sum of the four components (one for 4 
each assumption) and compared to a 4 degree-of-freedom chi-square distribution. The formula for 5 
each component and further details can be found in the original manuscript proposing the method 6 
[37]. The null hypothesis for the global test is that all four assumptions hold, and the alternative 7 
hypothesis is that at least one does not (i.e. a significant p-value indicates that a linear model is not 8 
appropriate). In order to assess how DNAm sites on the EPIC array performed across these five tests 9 
we plotted Quantile-Quantile (QQ) plots of the observed vs expected p-values. To characterize sites 10 
which perform poorly in these tests we visualized correlations between the p-values from the five 11 
gvlma tests and both the mean level of DNAm and two measures of variance (standard deviation and 12 
range of the middle 80% of values). For the purpose of assessing which assumptions are most 13 
commonly violated, and which are most commonly violated simultaneously, we applied the 14 
experiment wide p-value threshold derived in the previous sections (P < 9.42x10
-8
), to identify sites 15 
that reject the assumptions of linear regression. Finally to investigate the impact of violating the 16 
assumptions of linear regression, we calculated the mean rank across the 1000 null EWAS 17 
permutations as an indicator of how likely a site was to be associated by chance and any bias in 18 
association analyses. These mean ranks were then compared with the p-values of the gvlma tests.  19 
 20 
Estimating statistical power for EPIC array studies 21 
Power calculations were performed for each of the 804,826 sites in the dataset using the function 22 
pwr.t.test from the R package pwr [55]. We consider the scenario with a binary outcome (i.e. case 23 
control study), using a two-sample t-test to compare the means of the two groups where the null 24 
hypothesis of each test is that the means of the two groups are equal. To calculate power, the 25 
parameters sample size, effect size and significance level were provided. The significance level was 26 
set as our previously calculated experiment-wide threshold of 9.42x10
-8
. The effect size was provided 27 
as Cohen’s d, which is the expected difference between the two group means divided by their pooled 28 
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standard deviation [56]. In order to get a power estimate for the overall study, calculations were 1 
performed for every site individually using that site’s variance estimated from the Understanding 2 
Society dataset, for two different mean differences (2% and 5%). Power calculations were also 3 
performed for a range of total sample sizes (n = 100, 200, 500, 1000, 2000 and 5000) consisting of 4 
equal numbers of cases and controls. For each combination of parameters (sample size and mean 5 
difference), we calculated the percentage of sites that had sufficient statistical power across the full 6 
range of possible values (0-100%). While we only present results for a subset of the possible scenarios 7 
as a guide to the power of a typical EWAS study, we have also developed an R shiny app [7] to allow 8 
users to perform bespoke power calculations 9 
(https://epigenetics.essex.ac.uk/shiny/EPICDNAmPowerCalcs/). In this app, the user can specify 10 
sample size and mean difference to generate a summary results table and downloadable figure. As 11 
performing >800,000 power calculations is time consuming, the app uses a binning method, grouping 12 
sites with similar variances and plotting a smoothed curve, to speed up the calculation. For more 13 
accurate results the user can increase the number of bins, or chose to calculate the power for all sites 14 
individually. There is also an option to search for a specific DNAm site of interest and calculate its 15 
power under user defined parameters.  16 
 17 
Figure Legends 18 
 19 
Figure 1: Subsampling sites on the EPIC array to estimate a genome-wide significance 20 
threshold. Line graphs depicting the relationship between the number of EPIC array DNA 21 
methylation sites (x-axis) and A) the 5% family-wise error rate (FWER) (-log10(p-values); y-axis) and 22 
B) the mean effective number of tests (y-axis) estimated from 1000 simulated null association studies. 23 
Error bars present the 95% confidence intervals from 1000 simulations. The final point includes all 24 
DNA methylation sites on the EPIC array and therefore could not be resampled to generate a 25 
confidence interval. 26 
 27 
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Figure 2: Extrapolation to a genome-wide significance threshold. Line graphs depicting the 1 
relationship between the number of DNA methylation sites (x-axis) and A) the effective number of 2 
independent tests (y-axis) and B) the multiple testing corrected threshold (-log10(p-value); y-axis) 3 
estimated after fitting a Monod function to the observed data presented in Figure 1B. The observed 4 
values are plotted as the solid black line, and the estimated Monod model is plotted as a dashed line. 5 
The grey shaded region represents the 95% CI created by fitting a Monod model to the 95% CI of the 6 
subsampled data. The blue horizontal line represents the estimated asymptote of the Monod model of 7 
5,803,067 independent tests equivalent to a genome-wide significance threshold of 8.62x10
-9
. 8 
 9 
Figure 3: Overlap of significant violations of linear regression assumptions. Venn diagram 10 
depicting the overlap of DNA methylation sites significant for each test of a linear assumption (P < 11 
9.42x10
-8
). Presented are the number of overlapping DNA methylation sites along with the percentage 12 
of all tested sites shown in brackets.  13 
 14 
Figure 4: Comparison of tests of linear regression assumptions across the distribution of DNA 15 
methylation levels. Boxplots of –log10(p-value) for each of the 5 tests (a) global (b) skewness (c) 16 
kurtosis (d) link function and (e) heteroskedasticity for groups of DNA methylation sites binned by 17 
their mean DNA methylation level. The boxes are coloured by their mean –log10(p-value) from light 18 
yellow (low) to red (high). 19 
 20 
Figure 5: Comparison of tests of linear regression assumptions against DNA methylation 21 
variability. Boxplots of –log10(p-value) for each of the 5 tests (a) global (b) skewness (c) kurtosis (d) 22 
link function and (e) heteroscedasticity for groups of DNA methylation sites binned by their standard 23 
deviation. The boxes are coloured by their mean –log10(p-value) from light yellow (low) to red (high). 24 
 25 
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Figure 6: Comparison of tests of linear regression assumptions with bias in DNA methylation 1 
association studies. Scatterplots of –log10(p-value) (y-axis) from the (a) global (b) skewness (c) 2 
kurtosis (d) link function and (e) heteroskedasticity tests performed in the R gvlma package against 3 
average (mean) ranking from 1000 simulated null association studies (x-axis) for all DNA 4 
methylation sites. Each point represents a single site, and the color represents the density of points 5 
plotted at that position (low density in grey to high density in yellow). 6 
 7 
Figure 7: Power curves of typical DNA methylation studies. Line graphs depicting the proportion 8 
of sites on the EPIC array (y-axis) with sufficient power (x-axis) to detect a mean difference in DNA 9 
methylation between two groups of (a) 2% and (b) 5%. The different coloured lines represent 10 
different sample sizes where the value of N the total sample size set to be a 50:50 split between 11 
groups. 12 
 13 
  14 
25 
 
Supplemental Data 1 
 2 
Additional File 1: Supplementary figures S1-S10 (pdf) 3 
Additional File 2: Supplementary tables S1-S6 (pdf) 4 
 5 
Declarations 6 
Ethics approval and consent to participate 7 
Ethical approval for the Understanding Society nurse visit was obtained from the National Research 8 
Ethics Service (Reference: 10/H0604/2). Participants gave written consent for blood sampling. 9 
Consent for publication 10 
Not applicable 11 
Availability of data and material 12 
Individual level DNA methylation are available on application through the European Genome-13 
phenome Archive under accession EGAS00001001232 (https://www.ebi.ac.uk/ega/home). Specific 14 
details can be found here (https://www.understandingsociety.ac.uk/about/health/data). Phenotype 15 
linked to DNA methylation data are available through application to the METADAC 16 
(www.metadac.ac.uk).  Analysis scripts used in this manuscript are available on 17 
https://github.com/ejh243/EPICStatsPaper. 18 
Competing interests 19 
The authors declare that they have no competing interests 20 
Funding 21 
DNA methylation data generation in UKHLS was funded through enhancements to the Economic and 22 
Social Research council (ESRC) grants ES/K005146/1 and ES/N00812X/1.  MK is supported by the 23 
26 
 
University of Essex and ESRC (RES-596-28-0001). EH, JM and LS time on this project was 1 
supported by MRC grant K013807. The funding bodies played no role in the design of the study, data 2 
collection, analysis, and interpretation or in the writing of the manuscript. 3 
Authors' contributions 4 
EH designed the study. GM undertook primary statistical analyses with input from TG, YB, MK, LS, 5 
JM and EH. GM and EH drafted the manuscript. All authors read and approved the final manuscript. 6 
Acknowledgements 7 
Analysis was facilitated by access to the Genome high performance computing cluster at the 8 
University Of Essex School Of Biological Sciences. 9 
 10 
References 11 
1. Murphy TM, Mill J: Epigenetics in health and disease: heralding the EWAS era. Lancet 2014, 12 
383(9933):1952-1954. 13 
2. Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran 14 
S, Sandoval J et al: DNA methylation profiling in breast cancer discordant identical twins 15 
identifies DOK7 as novel epigenetic biomarker. Carcinogenesis 2013, 34(1):102-108. 16 
3. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, 17 
Webster M et al: The human colon cancer methylome shows similar hypo- and 18 
hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009, 19 
41(2):178-186. 20 
4. Lange CP, Campan M, Hinoue T, Schmitz RF, van der Meulen-de Jong AE, Slingerland H, Kok 21 
PJ, van Dijk CM, Weisenberger DJ, Shen H et al: Genome-scale discovery of DNA-22 
methylation biomarkers for blood-based detection of colorectal cancer. PLoS One 2012, 23 
7(11):e50266. 24 
5. Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, 25 
Taub M, Ronninger M et al: Epigenome-wide association data implicate DNA methylation 26 
as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 2013, 31(2):142-27 
147. 28 
6. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, Daunay A, Busato F, Mein CA, 29 
Manfras B et al: Identification of type 1 diabetes-associated DNA methylation variable 30 
positions that precede disease diagnosis. Plos Genet 2011, 7(9):e1002300. 31 
7. Murphy TM, Wong CC, Arseneault L, Burrage J, Macdonald R, Hannon E, Fisher HL, Ambler A, 32 
Moffitt TE, Caspi A et al: Methylomic markers of persistent childhood asthma: a 33 
longitudinal study of asthma-discordant monozygotic twins. Clin Epigenetics 2015, 7:130. 34 
8. Pidsley R, Viana J, Hannon E, Spiers HH, Troakes C, Al-Saraj S, Mechawar N, Turecki G, 35 
Schalkwyk LC, Bray NJ et al: Methylomic profiling of human brain tissue supports a 36 
neurodevelopmental origin for schizophrenia. Genome Biol 2014, 15(10):483. 37 
27 
 
9. Hannon E, Dempster E, Viana J, Burrage J, Smith AR, Macdonald R, St Clair D, Mustard C, 1 
Breen G, Therman S et al: An integrated genetic-epigenetic analysis of schizophrenia: 2 
evidence for co-localization of genetic associations and differential DNA methylation. 3 
Genome Biol 2016, 17(1):176. 4 
10. Ladd-Acosta C, Hansen KD, Briem E, Fallin MD, Kaufmann WE, Feinberg AP: Common DNA 5 
methylation alterations in multiple brain regions in autism. Mol Psychiatry 2014, 19(8):862-6 
871. 7 
11. Berko ER, Suzuki M, Beren F, Lemetre C, Alaimo CM, Calder RB, Ballaban-Gil K, Gounder B, 8 
Kampf K, Kirschen J et al: Mosaic epigenetic dysregulation of ectodermal cells in autism 9 
spectrum disorder. Plos Genet 2014, 10(5):e1004402. 10 
12. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, Eaton ML, Keenan BT, 11 
Ernst J, McCabe C et al: Alzheimer's disease: early alterations in brain DNA methylation at 12 
ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 2014, 17(9):1156-1163. 13 
13. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, Troakes C, Al-Sarraj S, 14 
Burrage J, Macdonald R et al: Methylomic profiling implicates cortical deregulation of ANK1 15 
in Alzheimer's disease. Nat Neurosci 2014, 17(9):1164-1170. 16 
14. Mill J, Heijmans BT: From promises to practical strategies in epigenetic epidemiology. Nat 17 
Rev Genet 2013, 14(8):585-594. 18 
15. Relton CL, Davey Smith G: Epigenetic epidemiology of common complex disease: prospects 19 
for prediction, prevention, and treatment. PLoS Med 2010, 7(10):e1000356. 20 
16. Rakyan VK, Down TA, Balding DJ, Beck S: Epigenome-wide association studies for common 21 
human diseases. Nat Rev Genet 2011, 12(8):529-541. 22 
17. Laird PW: Principles and challenges of genomewide DNA methylation analysis. Nat Rev 23 
Genet 2010, 11(3):191-203. 24 
18. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM: Comparison of Beta-value and 25 
M-value methods for quantifying methylation levels by microarray analysis. BMC 26 
Bioinformatics 2010, 11:587. 27 
19. Birney E, Smith GD, Greally JM: Epigenome-wide Association Studies and the Interpretation 28 
of Disease -Omics. PLoS Genet 2016, 12(6):e1006105. 29 
20. Panni T, Mehta AJ, Schwartz JD, Baccarelli AA, Just AC, Wolf K, Wahl S, Cyrys J, Kunze S, 30 
Strauch K et al: A Genome-Wide Analysis of DNA Methylation and Fine Particulate Matter 31 
Air Pollution in Three Study Populations: KORA F3, KORA F4, and the Normative Aging 32 
Study. Environ Health Perspect 2016. 33 
21. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O'Donovan MC, Bray NJ, Mill J: 34 
Methylomic trajectories across human fetal brain development. Genome Res 2015, 35 
25(3):338-352. 36 
22. Cardenas A, Houseman EA, Baccarelli AA, Quamruzzaman Q, Rahman M, Mostofa G, Wright 37 
RO, Christiani DC, Kile ML: In utero arsenic exposure and epigenome-wide associations in 38 
placenta, umbilical artery, and human umbilical vein endothelial cells. Epigenetics 2015, 39 
10(11):1054-1063. 40 
23. Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, Davey Smith G, Hughes AD, 41 
Chaturvedi N, Relton CL: Differences in smoking associated DNA methylation patterns in 42 
South Asians and Europeans. Clin Epigenetics 2014, 6(1):4. 43 
24. Ong ML, Holbrook JD: Novel region discovery method for Infinium 450K DNA methylation 44 
data reveals changes associated with aging in muscle and neuronal pathways. Aging Cell 45 
2014, 13(1):142-155. 46 
25. Heyn H, Moran S, Hernando-Herraez I, Sayols S, Gomez A, Sandoval J, Monk D, Hata K, 47 
Marques-Bonet T, Wang L et al: DNA methylation contributes to natural human variation. 48 
Genome Res 2013, 23(9):1363-1372. 49 
26. Noble WS: How does multiple testing correction work? Nat Biotechnol 2009, 27(12):1135-50 
1137. 51 
28 
 
27. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and Powerful 1 
Approach to Multiple Testing. Journal of the Royal Statistical Society 1995, 57(1):289-300. 2 
28. Moskvina V, Schmidt KM: On multiple-testing correction in genome-wide association 3 
studies. Genet Epidemiol 2008, 32(6):567-573. 4 
29. Zaghlool SB, Al-Shafai M, Al Muftah WA, Kumar P, Falchi M, Suhre K: Association of DNA 5 
methylation with age, gender, and smoking in an Arab population. Clin Epigenetics 2015, 6 
7(1):6. 7 
30. Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP: 8 
Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals 9 
persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell 10 
populations. Plos Genet 2013, 9(8):e1003678. 11 
31. Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan ST, Afzal U, Scott J, Jarvelin MR, Elliott P 12 
et al: A coherent approach for analysis of the Illumina HumanMethylation450 BeadChip 13 
improves data quality and performance in epigenome-wide association studies. Genome 14 
Biol 2015, 16:37. 15 
32. Saffari A, Silver MJ, Zavattari P, Moi L, Columbano A, Meaburn EL, Dudbridge F: Estimation 16 
of a significance threshold for epigenome-wide association studies. Genet Epidemiol 2018, 17 
42(1):20-33. 18 
33. Gorrie-Stone TJ, Smart MC, Saffari A, Malki K, Hannon E, Burrage J, Mill J, Kumari M, 19 
Schalkwyk LC: Bigmelon: Tools for analysing large DNA methylation datasets. 20 
Bioinformatics 2018:bty713-bty713. 21 
34. Hannon E, Gorrie-Stone TJ, Smart MC, Burrage J, Hughes A, Bao Y, Kumari M, Schalkwyk LC, 22 
Mill J: Leveraging DNA-Methylation Quantitative-Trait Loci to Characterize the Relationship 23 
between Methylomic Variation, Gene Expression, and Complex Traits. Am J Hum Genet 24 
2018, 103(5):654-665. 25 
35. Dudbridge F, Gusnanto A: Estimation of significance thresholds for genomewide 26 
association scans. Genet Epidemiol 2008, 32(3):227-234. 27 
36. Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, Mangino M, Zhai G, Zhang F, Valdes A et 28 
al: Epigenome-wide scans identify differentially methylated regions for age and age-29 
related phenotypes in a healthy ageing population. PLoS Genet 2012, 8(4):e1002629. 30 
37. Peña EA, Slate EH: Global Validation of Linear Model Assumptions. J Am Stat Assoc 2006, 31 
101(473):341. 32 
38. Glossop JR, Nixon NB, Emes RD, Haworth KE, Packham JC, Dawes PT, Fryer AA, Mattey DL, 33 
Farrell WE: Epigenome-wide profiling identifies significant differences in DNA methylation 34 
between matched-pairs of T- and B-lymphocytes from healthy individuals. Epigenetics 35 
2013, 8(11):1188-1197. 36 
39. Fryer AA, Emes RD, Ismail KM, Haworth KE, Mein C, Carroll WD, Farrell WE: Quantitative, 37 
high-resolution epigenetic profiling of CpG loci identifies associations with cord blood 38 
plasma homocysteine and birth weight in humans. Epigenetics 2011, 6(1):86-94. 39 
40. Gao Z, Fu HJ, Zhao LB, Sun ZY, Yang YF, Zhu HY: Aberrant DNA methylation associated with 40 
Alzheimer's disease in the superior temporal gyrus. Exp Ther Med 2018, 15(1):103-108. 41 
41. Ladd-Acosta C, Hansen K, Briem E, Fallin M, Kaufmann W, Feinberg A: Common DNA 42 
methylation alterations in multiple brain regions in autism. Molecular Psychiatry 2014, 43 
19(8):862-871. 44 
42. Triche TJ, Laird PW, Siegmund KD: Beta regression improves the detection of differential 45 
DNA methylation for epigenetic epidemiology. bioRxiv 2016:054643. 46 
43. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Andrews SV, Hougaard DM, 47 
Bresnahan M, Mors O, Hollegaard MV et al: Elevated polygenic burden for autism is 48 
associated with differential DNA methylation at birth. Genome Med 2018, 10(1):19. 49 
29 
 
44. Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y et al: 1 
Epigenome-wide association study of body mass index, and the adverse outcomes of 2 
adiposity. Nature 2017, 541(7635):81-86. 3 
45. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, Guan W, Xu T, Elks 4 
CE, Aslibekyan S et al: Epigenetic Signatures of Cigarette Smoking. Circ Cardiovasc Genet 5 
2016, 9(5):436-447. 6 
46. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, Reese SE, Markunas CA, 7 
Richmond RC, Xu CJ et al: DNA Methylation in Newborns and Maternal Smoking in 8 
Pregnancy: Genome-wide Consortium Meta-analysis. Am J Hum Genet 2016, 98(4):680-696. 9 
47. Tsai PC, Bell JT: Power and sample size estimation for epigenome-wide association scans to 10 
detect differential DNA methylation. Int J Epidemiol 2015. 11 
48. R Development Core Team: R: A Language and Environment for Statistical Computing. In. 12 
Vienna, Austria: R Foundation for Statistical Computing; 2008. 13 
49. Gorrie-Stone TJ, Smart MC, Saffari A, Malki K, Hannon E, Burrage J, Mill J, Kumari M, 14 
Schalkwyk LC: Bigmelon: tools for analysing large DNA methylation datasets. Bioinformatics 15 
2019, 35(6):981-986. 16 
50. Pidsley R, Wong CCY, Volta M, Lunnon K, Mill J, Schalkwyk LC: A data-driven approach to 17 
preprocessing Illumina 450K methylation array data. Bmc Genomics 2013, 14. 18 
51. Horvath S: DNA methylation age of human tissues and cell types. Genome Biol 2013, 19 
14(10):R115. 20 
52. McCartney DL, Walker RM, Morris SW, M. MA, J. PD, L. EK: Identification of polymorphic 21 
and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. 22 
Genomics Data 2016, 9(September):22-24. 23 
53. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke 24 
JK, Kelsey KT: DNA methylation arrays as surrogate measures of cell mixture distribution. 25 
BMC Bioinformatics 2012, 13:86. 26 
54. Koestler DC, Christensen B, Karagas MR, Marsit CJ, Langevin SM, Kelsey KT, Wiencke JK, 27 
Houseman EA: Blood-based profiles of DNA methylation predict the underlying 28 
distribution of cell types: a validation analysis. Epigenetics 2013, 8(8):816-826. 29 
55. Champely S: pwr: Basic Functions for Power Analysis. In., 1.2-2 edn. https://CRAN.R-30 
project.org/package=pwr; 2018. 31 
56. Cohen J: Statistical power analysis for the behavioral sciences  . , Second edn. Hillsdale, N.J.: 32 
Lawrence Erlbaum Associates; 1988. 33 
 34 
